Skip to content

Author

K. Kanaoka

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Early Vericiguat Initiation After First Hospitalization for Heart Failure With Reduced Ejection Fraction

Background Hospitalization for the first episode of heart failure with reduced ejection fraction (HFrEF) represents an important opportunity to initiate evidence-based therapies. In this study, we aimed to clarify the role of vericiguat after first hospitalization for HFrEF in routine clinical practice. Methods and Res...

H. Matsuzoe, K. Matsumura, A. Suzuki et al. · 0 citations
Nov 2026

Abstract 8662: Advanced Heart Failure Care Status and Outcomes in Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair

Background: Mitral transcatheter valve edge-to-edge repair (M-TEER) has become a treatment option for heart failure (HF) patients with mitral regurgitation (MR) at high surgical risk. However, limited data exist for the association between hospitalization at a center providing advanced HF therapy and clinical outcom...

K. Takegawa, Y. Iwanaga, K. Kanaoka et al. · 0 citations
Open access Oct 2026

Postoperative Mortality and Risk Factors in Adults With Congenital Heart Disease Undergoing Cardiovascular Surgery

Background Patients with adult congenital heart disease (ACHD) are prone to complications and usually require surgical intervention, but the surgical risk factors remain poorly defined. Methods and Results We analyzed data from April 2013 to March 2023 in the nationwide Japanese Registry of All Cardiac and Vascular Dis...

Takumi Osawa, T. Machino-Ohtsuka, Keitaro Kume et al. · 0 citations
Open access Oct 2026

Clopidogrel or prasugrel vs. aspirin monotherapy for long-term secondary prevention after percutaneous coronary intervention for acute coronary syndrome

Optimal long-term antiplatelet monotherapy in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) remains a subject of ongoing debate. In particular, it remains unclear whether different P2Y12 inhibitors provide comparable clinical benefits when used as long-term mon...

Y. Iwanaga, K. Kanaoka, K. Takegawa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.